Liraglutide
Injection · trading as Victoza
Current Active — Day 1031
Lower impact — Multiple manufacturers (3 known suppliers) produce this drug, which may allow alternative sourcing.
FDA shortage record
- Substance
- Liraglutide
- Brand name
- Victoza
- Manufacturers / suppliers
-
- Novo Nordisk
- Novo Nordisk, Inc.
- Dosage form
- Injection
- Presentation
- Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)
- Route(s)
- SUBCUTANEOUS
- Therapeutic category
- Endocrinology/Metabolism
- Package NDC
0169-4060-12- Initially posted
- 07/18/2023
- Days on shortage list
- 1031
- Current FDA status
- Current
- Shortage entries (current dataset)
- 3 records for Liraglutide — repeat offender
Reason and context
Reason reported: Delay in shipping of the drug
Estimated shortage duration TBD
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 833-493-4689.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
5a9ef4ea-c76a-4d34-a604-27c5b505f5a4). - FDA UNII identifier:
839I73S42A. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.